DaVita (NYSE:DVA) Stock Price Expected to Rise, TD Cowen Analyst Says

by · The Cerbat Gem

DaVita (NYSE:DVA – Get Free Report) had its price target lifted by analysts at TD Cowen from $144.00 to $201.00 in a research note issued to investors on Monday,MarketScreener reports. TD Cowen’s target price indicates a potential downside of 0.16% from the company’s previous close.

Other analysts have also recently issued research reports about the company. Deutsche Bank Aktiengesellschaft raised DaVita from a “hold” rating to a “buy” rating and raised their price target for the company from $126.00 to $220.00 in a report on Wednesday, May 6th. Zacks Research raised shares of DaVita from a “hold” rating to a “strong-buy” rating in a research note on Thursday. Wall Street Zen upgraded DaVita from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. Truist Financial lifted their target price on shares of DaVita from $158.00 to $205.00 and gave the stock a “hold” rating in a research report on Friday. Finally, Barclays raised their price objective on DaVita from $158.00 to $194.00 and gave the company an “equal weight” rating in a research note on Thursday. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $199.17.

View Our Latest Stock Analysis on DVA

DaVita Stock Performance

NYSE:DVA opened at $201.33 on Monday. The firm has a market cap of $12.93 billion, a price-to-earnings ratio of 18.70, a price-to-earnings-growth ratio of 0.65 and a beta of 0.84. DaVita has a 52 week low of $101.00 and a 52 week high of $199.27. The firm has a 50-day moving average price of $153.03 and a two-hundred day moving average price of $132.70.

DaVita (NYSE:DVA – Get Free Report) last issued its earnings results on Tuesday, May 5th. The company reported $2.87 earnings per share for the quarter, topping analysts’ consensus estimates of $2.33 by $0.54. DaVita had a net margin of 5.65% and a negative return on equity of 270.37%. The firm had revenue of $3.42 billion during the quarter, compared to analyst estimates of $3.36 billion. During the same quarter last year, the business earned $2.00 earnings per share. The company’s quarterly revenue was up 6.0% on a year-over-year basis. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. As a group, sell-side analysts forecast that DaVita will post 15.07 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Arrowstreet Capital Limited Partnership lifted its holdings in shares of DaVita by 114.9% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 1,190,000 shares of the company’s stock valued at $135,196,000 after purchasing an additional 636,191 shares during the last quarter. Norges Bank bought a new stake in DaVita during the 4th quarter worth approximately $49,164,000. Corient Private Wealth LLC lifted its holdings in DaVita by 1,493.1% during the fourth quarter. Corient Private Wealth LLC now owns 358,299 shares of the company’s stock valued at $40,706,000 after purchasing an additional 335,809 shares in the last quarter. Man Group plc boosted its position in shares of DaVita by 1,608.6% in the second quarter. Man Group plc now owns 285,809 shares of the company’s stock worth $40,713,000 after purchasing an additional 269,081 shares during the period. Finally, Neuberger Berman Group LLC increased its stake in shares of DaVita by 138.5% in the third quarter. Neuberger Berman Group LLC now owns 463,250 shares of the company’s stock worth $61,502,000 after purchasing an additional 269,015 shares in the last quarter. 90.12% of the stock is owned by hedge funds and other institutional investors.

About DaVita

(Get Free Report)

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.

See Also